Online inquiry

IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12720MR)

This product GTTS-WQ12720MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets DLL4&VEGFA gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_019074.4; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 54567; 7422
UniProt ID Q9NR61; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12720MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1345MR IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABT-806
GTTS-WQ3327MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AT-001
GTTS-WQ6697MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ14378MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ8904MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IGE25
GTTS-WQ6800MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DS-8201
GTTS-WQ10227MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LFB-R593
GTTS-WQ6278MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CS-1001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW